{"nctId":"NCT01232920","briefTitle":"First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial","startDateStruct":{"date":"2010-10"},"conditions":["Uveitis"],"count":80,"armGroups":[{"label":"Methotrexate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Methotrexate"]},{"label":"Mycophenolate mofetil","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mycophenolate mofetil"]}],"interventions":[{"name":"Methotrexate","otherNames":[]},{"name":"Mycophenolate mofetil","otherNames":["Cellcept"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-infectious anterior, intermediate, posterior or panuveitis\n* Active uveitis within the last 60 days (defined by the presence of any of the following according to SUN criteria: ≥ 1+ anterior chamber cells, anterior vitreous cells, vitreous haze, active retinal or choroidal lesions)\n* Prednisone dose ≥ 15 mg/day\n* History of corticosteroid taper failure (inability to taper to prednisone 10 mg or less) or obvious chronic disease necessitating corticosteroid-sparing immunosuppressive treatment\n\nExclusion Criteria:\n\n* Any infectious cause of uveitis\n* Tuberculosis: Evidence of active TB (PPD and CXR required - latent TB patients are still eligible)\n* Positive for Hepatitis: HBsAg and/or Hep C antibody\n* Positive for Syphilis: RPR/VDRL and/or FTA-ABS\n* Abnormal CBC (\\<2500 WBC or \\<75,000 Plts or \\<10 Hgb)\n* Abnormal liver and/or kidney tests (ALT/AST \\>2x normal or CR\\>1.5)\n* Pregnancy or breast-feeding (blood or urine pregnancy test for all females, excluding those who are post-menopausal)\n* Chronic hypotony (IOP \\< 5 mm Hg for \\> 3 months)\n* Prior use of any immunosuppressive drug for the treatment of uveitis in the past 6 months\n* Prior failed treatment with methotrexate or mycophenolate mofetil\n* Periocular or intravitreal corticosteroid injection in the past 3 months\n* Fluocinolone acetonide implant surgery in either eye in \\< 3 years\n* Intraocular surgery in \\< 30 days, or any ocular surgery scheduled during the 6-month study period\n* VA of hand motions or worse in better eye\n* \\< 16 years of age at enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Achieving Treatment Success","description":"TREATMENT SUCCESS is defined as controlled ocular inflammation in both eyes with less than or equal to 10 mg/day of prednisone and/or 2 topical steroid drops/day sustained for 2 visits separated by at least 28 days (control of inflammation and prednisone dose must be achieved by 5-month visit and sustained until 6-month visit).\n\nDiscontinuation of study medication at any time due to efficacy, tolerability, or safety may result in a declaration of TREATMENT FAILURE. Note that all patients will be classified as either a treatment success or failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Control of Inflammation","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Best Spectacle-corrected Visual Acuity (BSCVA)","description":"Change in best spectacle-corrected visual acuity (BSCVA) from baseline. Analysis on eye level","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.33"},{"groupId":"OG001","value":"-0.19","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Number of Eyes With Resolution of Macular Edema","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["Headache","Fever for 12 hours","Nausea","Diarrhea","Cataract"]}}}